|
Long-term growth and development in 268 bevacizumab (BEV)-treated and 135 control pediatric/adolescent patients (pts): An integrated analysis. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Proacta (Inst) |
Travel, Accommodations, Expenses - Proacta |
|
|
No Relationships to Disclose |
|
|
Research Funding - Amgen (Inst); Celgene (Inst); Merck (Inst); Pfizer (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Proacta |
|
|
|
|
|
Employment - Proacta; Proacta (I) |
Stock and Other Ownership Interests - Proacta; Proacta (I) |
|
|
|
Stock and Other Ownership Interests - Proacta |
|
Travel, Accommodations, Expenses - Proacta |